This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Generation Bio Co. (GBIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Generation Bio (GBIO) delivered earnings and revenue surprises of -14.81% and 26.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 0% and 89.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Generation Bio (GBIO) delivered earnings and revenue surprises of -211.11% and 34.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -29.27% and 5.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of 4.08% and 88.27%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -35.90% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio
by Zacks Equity Research
Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.
Can Generation Bio Co. (GBIO) Climb 184% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 183.8% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Generation Bio Co. (GBIO) Could Surge 176%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 176% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -4.76% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 174% Upside in Generation Bio Co. (GBIO): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 173.7% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Generation Bio Co. (GBIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -17.31% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Upgraded to Buy: Here's Why
by Zacks Equity Research
Generation Bio Co. (GBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Much Upside is Left in Generation Bio Co. (GBIO)? Wall Street Analysts Think 505%
by Zacks Equity Research
The consensus price target hints at a 504.9% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Earnings Season Could Be Great for Generation Bio (GBIO)
by Zacks Equity Research
Generation Bio (GBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Generation Bio (GBIO) Catches Eye: Stock Jumps 6.1%
by Zacks Equity Research
Generation Bio (GBIO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.